Dr. Hui Zhang is a globally recognized leader in proteomics and glycoproteomics and a Professor at Johns Hopkins University, where she directs major mass spectrometry and biomarker discovery programs. She pioneered broadly reactive PTM antibodies, immunoaffinity mass spectrometry, and modern glycoproteomic technologies. Her innovations underpin multiple foundational U.S. patents and have enabled biomarker discovery and proteogenomic studies across many cancers. Dr. Zhang has published ~300 papers, including in Nature Biotechnology, Cell, and Cancer Cell, with over 30,000 citations, establishing her as a world authority in quantitative proteomics.
My mission is to advance rigorous, quantitative proteomics and glycoproteomics technologies that translate directly into clinically actionable biomarkers. I am committed to building robust, reproducible platforms that bridge fundamental discovery and real-world medical impact.
Co-leading Complete Omics, my goal is to standardize and scale high-performance proteomic technologies, enabling ultra-deep, clinically deployable molecular measurements to support precision diagnostics and personalized disease management.
Biography
Pioneering leaders in clinical proteomics, translating deep scientific innovation into robust, clinically deployable assays.
Contact Form